Prof. Dr. Juliane Walz | Immunotechnology | Best Researcher Award
W3 Professor and Medical Director at Department of Peptide-based Immunotherapy | University Hospital Tübingen | Germany
Prof. Dr. Juliane Walz is a distinguished scholar and medical researcher recognized for her pioneering contributions in peptide-based immunotherapy, translational oncology, and infectious disease immunity, establishing herself as a leader at the forefront of clinical and experimental medicine. Prof. Dr. Juliane Walz completed her medical education with highest distinction, further advancing her academic credentials through rigorous postdoctoral training and habilitation, which solidified her expertise in translational immunology. Prof. Dr. Juliane Walz currently serves as W3 Professor for Peptide-based Immunotherapy and Medical Director of the Clinical Cooperation Unit for Translational Immunology at the University Hospital Tübingen, where she has built a reputation for integrating clinical practice with groundbreaking research. Prof. Dr. Juliane Walz’s research interests encompass tumor immunology, T-cell biology, biomarker discovery, and the development of novel immunotherapeutic strategies targeting cancer and viral infections, with a special focus on clinical applications that directly benefit patients. Prof. Dr. Juliane Walz has developed advanced research skills in immunopeptidomics, epitope identification, biomarker validation, clinical trial design, and translational research methodologies that connect laboratory insights with real-world therapeutic solutions. Prof. Dr. Juliane Walz has published in high-impact peer-reviewed journals, with a record of 671 citations by 526 documents, authoring 13 documents and achieving an h-index of 9, reflecting the strong visibility and influence of her work within the global scientific community. Prof. Dr. Juliane Walz has been honored with multiple awards and recognitions for excellence in medical research, innovative immunotherapy approaches, and academic leadership, affirming her status as a leading figure in her field. Prof. Dr. Juliane Walz also actively mentors students, leads collaborative projects across international institutions, and contributes to advancing academic and clinical networks that shape the future of immunology and oncology. In conclusion, Prof. Dr. Juliane Walz’s career embodies an inspiring combination of rigorous education, impactful professional experience, diverse research interests, advanced research skills, and well-deserved awards and honors, making her an influential figure whose contributions continue to push the boundaries of modern medicine and translational research.
Featured Publications
Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., Roerden, M., … Walz, J. S. (2021). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nature Immunology, 22(1), 74–85.
Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., … Walz, J. S. (2022). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 601(7894), 617–622.
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., … Walz, J. S. (2021). HLA Ligand Atlas: A benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. Journal for Immunotherapy of Cancer, 9(4), e002071.
Schuster, H., Peper, J. K., Boesmueller, H. C., Roehle, K., Backert, L., Bilich, T., … Walz, J. S. (2017). The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences, 114(46), E9942–E9951.
Nelde, A., Rammensee, H. G., & Walz, J. S. (2021). The peptide vaccine of the future. Molecular & Cellular Proteomics, 20, 100022.
Kowalewski, D. J., Schuster, H., Backert, L., Berlin, C., Kahn, S., Kanz, L., … Walz, J. S. (2015). HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences, 112(2), E166–E175.
Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., … Walz, J. S. (2021). T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine, 13(590), eabf7517.